Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 8, 2012, Pages 643-649

  El Bassossy, Hany M ^a,b   Abo Warda, Shaymaa M ^a   Fahmy, Ahmed ^a  

^a Zagazig University   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Aorta; Diabetes; Hypertension; Peroxisome proliferator activated receptor ; Vascular reactivity

Indexed keywords

ACETYLCHOLINE; ADVANCED GLYCATION END PRODUCT; CALCIUM; CHOLESTEROL; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PHENYLEPHRINE; POTASSIUM CHLORIDE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL REACTIVITY; CALCIUM CELL LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERTENSION; MALE; NONHUMAN; PULSE RATE; RAT; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; TRIACYLGLYCEROL BLOOD LEVEL; VASOCONSTRICTION; VASODILATATION;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD VESSELS; CALCIUM; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; NITRIC OXIDE; POTASSIUM CHLORIDE; PPAR GAMMA; RATS; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 84864323690     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2012.05724.x     Document Type: Article

References (43)

1. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc. Res. 2011; 93: 583-93.
2. Rodriguez-Manas L, Angulo J, Vallejo S et al. Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. Diabetologia 2003; 46: 556-66.
3. Ellis A, Cheng ZJ, Li Y et al. Effects of a Western diet versus high glucose on endothelium-dependent relaxation in murine micro- and macro-vasculature. Eur. J. Pharmacol. 2008; 601: 111-17.
4. Qian LB, Wang HP, Chen Y et al. Luteolin reduces high glucose-mediated impairment of endothelium-dependent relaxation in rat aorta by reducing oxidative stress. Pharmacol. Res. 2010; 61: 281-7.
5. Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab. Vasc. Dis. Res. 2007; 4: 84-8.
6. Dobesh PP. Managing hypertension in patients with type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 2006; 63: 1140-9.
7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703-13.
8. Reginato MJ, Lazar MA. Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol. Metab. 1999; 10: 9-13.
9. Marx N, Walcher D. Vascular effects of PPAR[gamma] activators: From bench to bedside. Prog. Lipid Res. 2007; 46: 283-96.
10. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ. Res. 2004; 94: 1168-78.
11. Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. 1998; 246: 370-4.
12. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-{gamma}-mediated effects in the vasculature. Circ. Res. 2008; 102: 283-94.
13. Silva-Junior GO, Torres TS, Mendonca LS, Mandarim DL. Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats. Exp. Toxicol. Pathol. 2011; 63: 1-7.
14. Sampathkumar R, Balasubramanyam M, Rema M, Premanand C, Mohan V. A novel advanced glycation index and its association with diabetes and microangiopathy. Metabolism 2005; 54: 1002-7.
15. El-Bassossy HM, Fahmy A, Badawy D. Cinnamaldehyde protects from the hypertension associated with diabetes. Food Chem. Toxicol. 2011; 49: 3007-12.
16. El-Bassossy HM, El-Maraghy NN, El-Fayoumi HM, Watson ML. Haem oxygenase-1 induction protects against tumour necrosis factor alpha impairment of endothelial-dependent relaxation in rat isolated pulmonary artery. Br. J. Pharmacol. 2009; 158: 1527-35.
17. Brown JD, Plutzky J. Peroxisome proliferator activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007; 115: 518-33.
18. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007; 356: 2457-71.
19. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes: An interim analysis. N. Engl. J. Med. 2007; 357: 28-38.
20. Mansour SM, Bahgat AK, El-Khatib AS, Khayyal MT. Ginkgo biloba extract (Egb 761) normalizes hypertension in 2K, 1C hypertensive rats: Role of antioxidant mechanisms, ACE inhibiting activity and improvement of endothelial dysfunction. Phytomedicine 2011; 18: 641-7.
21. MacLeod KM. The effect of insulin treatment on changes in vascular reactivity in chronic, experimental diabetes. Diabetes 1985; 34: 1160-7.
22. Xavier FE, Davel AP, Rossoni LV, Vassallo DV. Time-dependent hyperreactivity to phenylephrine in aorta from untreated diabetic rats: Role of prostanoids and calcium mobilization. Vasc. Pharmacol. 2003; 40: 67-76.
23. Kinoshita Y, Saito M, Satoh I et al. General administration of cyclohexenonic long-chain fatty alcohol ameliorates hyperreactivity of STZ-induced diabetic rat aorta. Life Sci. 2006; 78: 1508-14.
24. Baluchnejadmojarad T, Roghani M, Homayounfar H, Hosseini M. Beneficial effect of aqueous garlic extract on the vascular reactivity of streptozotocin-diabetic rats. J. Ethnopharmacol. 2003; 85: 139-44.
25. El-Bassossy HM, Fahmy A, El-Fawal R. Arginase inhibition alleviates hypertension associated with diabetes: Effect on endothelial dependent relaxation and NO production. Vasc. Pharmacol. 2012; doi:10.1016/j.vph.2012.01.001.
26. Llorens S, Mendizabal Y, Nava E. Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension. Eur. J. Pharmacol. 2007; 575: 105-12.
27. Bagi Z, Koller A, Kaley G. PPAR{gamma} activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 2004; 286: H742-8.
28. El-Mas MM, El-Gowelli HM, Abd-Elrahman KS, Saad EI, Abdel-Galil AG, Abdel-Rahman AA. Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function. Biochem. Pharmacol. 2011; 81: 526-33.
29. Dhaunsi GS, Yousif MH, Akhtar S, Chappell MC, Diz DI, Benter IF. Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities. Eur. J. Pharmacol. 2010; 638: 108-14.
30. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484-90.
31. Clements RT, Sodha NR, Feng J et al. Impaired coronary microvascular dilation correlates with enhanced vascular smooth muscle MLC phosphorylation in diabetes. Microcirculation 2009; 16: 193-206.
32. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J. Physiol. 2000; 522: 177-85.
33. El-Bassossy HM, El-Moselhy MA, Mahmoud MF. Pentoxifylline alleviates vascular impairment in insulin resistance via TNF-α inhibition. Naunyn Schmiedebergs Arch. Pharmacol. 2011; 384: 277-85.
34. St-Pierre P, Bouffard L, Maheux P. Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model. Biochem. Pharmacol. 2004; 67: 1997-2004.
35. Giaginis C, Tsourouflis G, Theocharis S. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: Novel pharmacological agents in the treatment of ischemia reperfusion injury. Curr. Mol. Med. 2008; 8: 562-79.
36. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 1991; 87: 432-8.
37. Wong WT, Ng CH, Tsang SY, Huang Y, Chen ZY. Relative contribution of individual oxidized components in ox-LDL to inhibition on endothelium-dependent relaxation in rat aorta. Nutr. Metab. Cardiovasc. Dis. 2011; 21: 157-64.
38. Sobal G, Menzel EJ, Sinzinger H. Troglitazone inhibits long-term glycation and oxidation of low-density lipoprotein. J. Cardiovasc. Pharmacol. 2005; 46: 672-80.
39. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. Acta 2000; 301: 65-77.
40. Chang PC, Chen TH, Chang CJ, Hou CC, Chan P, Lee HM. Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int. 2004; 65: 1664-75.
41. Schaalan M, El-Abhar HS, Barakat M, El-Denshary ES. Westernized-like-diet-fed rats. Effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride. J. Diabetes Complicat. 2009; 23: 199-208.
42. Robins SJ, Rubins HB, Faas FH et al. Insulin resistance and cardiovascular events with low HDL cholesterol: The veterans affairs HDL intervention trial (VA-HIT). Diabetes Care 2003; 26: 1513-17.
43. Eliza J, Daisy P, Ignacimuthu S, Duraipandiyan V. Antidiabetic and antilipidemic effect of eremanthin from Costus speciosus (Koen.) Sm. in STZ-induced diabetic rats. Chem. Biol. Interact. 2009; 182: 67-72.